Healthcare of Ontario Pension Plan Trust Fund Invests $16.49 Million in Axsome Therapeutics, Inc. $AXSM

Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) during the 1st quarter, HoldingsChannel.com reports. The firm acquired 97,550 shares of the company’s stock, valued at approximately $16,488,000.

A number of other institutional investors and hedge funds have also bought and sold shares of AXSM. Price T Rowe Associates Inc. MD increased its position in shares of Axsome Therapeutics by 45.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,509,870 shares of the company’s stock valued at $275,763,000 after purchasing an additional 472,422 shares during the last quarter. Wellington Management Group LLP boosted its stake in Axsome Therapeutics by 84.1% in the third quarter. Wellington Management Group LLP now owns 1,334,560 shares of the company’s stock worth $162,082,000 after buying an additional 609,516 shares in the last quarter. Invesco Ltd. boosted its stake in Axsome Therapeutics by 28.6% in the fourth quarter. Invesco Ltd. now owns 1,273,494 shares of the company’s stock worth $232,591,000 after buying an additional 282,937 shares in the last quarter. Geode Capital Management LLC grew its position in Axsome Therapeutics by 1.3% during the fourth quarter. Geode Capital Management LLC now owns 1,010,249 shares of the company’s stock valued at $184,544,000 after acquiring an additional 12,549 shares during the last quarter. Finally, State Street Corp grew its position in Axsome Therapeutics by 5.8% during the second quarter. State Street Corp now owns 958,503 shares of the company’s stock valued at $100,058,000 after acquiring an additional 52,483 shares during the last quarter. 81.49% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

AXSM has been the subject of several recent research reports. Mizuho boosted their price target on shares of Axsome Therapeutics from $228.00 to $310.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 5th. Piper Sandler restated an “overweight” rating and set a $258.00 target price on shares of Axsome Therapeutics in a report on Monday, May 4th. Zacks Research lowered Axsome Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday, July 20th. Royal Bank Of Canada boosted their price objective on Axsome Therapeutics from $302.00 to $304.00 and gave the company an “outperform” rating in a research report on Tuesday, July 7th. Finally, Deutsche Bank Aktiengesellschaft set a $280.00 target price on shares of Axsome Therapeutics in a report on Tuesday, May 5th. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $261.48.

Insider Buying and Selling

In other news, COO Mark L. Jacobson sold 4,517 shares of the stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $227.94, for a total transaction of $1,029,604.98. Following the sale, the chief operating officer owned 4,517 shares in the company, valued at $1,029,604.98. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Mark Coleman sold 6,000 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $230.30, for a total transaction of $1,381,800.00. Following the sale, the director directly owned 35,140 shares of the company’s stock, valued at $8,092,742. This trade represents a 14.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 155,852 shares of company stock worth $37,230,112 over the last quarter. 20.60% of the stock is owned by insiders.

Axsome Therapeutics Price Performance

AXSM opened at $238.37 on Tuesday. The company has a current ratio of 1.39, a quick ratio of 1.32 and a debt-to-equity ratio of 2.27. The company has a market cap of $12.27 billion, a price-to-earnings ratio of -63.91 and a beta of 0.60. The stock has a fifty day simple moving average of $239.46 and a two-hundred day simple moving average of $201.27. Axsome Therapeutics, Inc. has a 12-month low of $96.09 and a 12-month high of $260.19.

Axsome Therapeutics (NASDAQ:AXSM) last released its earnings results on Monday, May 4th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.41). The business had revenue of $191.20 million for the quarter, compared to analysts’ expectations of $191.10 million. Axsome Therapeutics had a negative net margin of 26.59% and a negative return on equity of 267.16%. The company’s revenue for the quarter was up 57.4% compared to the same quarter last year. Research analysts predict that Axsome Therapeutics, Inc. will post -2.45 earnings per share for the current fiscal year.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.